The first authorised treatment for epidermolysis bullosa in Ireland has been made available, marking a major milestone for patients living with the painful rare skin condition.
Stakeholders at the AXIS Patient Access Conference in Dublin heard that Ireland must agree a clear operational roadmap to meet its 180-day reimbursement decision target.
